{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T20:37:18Z","timestamp":1772138238617,"version":"3.50.1"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2009,1,28]],"date-time":"2009-01-28T00:00:00Z","timestamp":1233100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Like aldosterone escape to ACE-inhibitors, adrenergic escape (AE) to \u03b2-blockers appears conceivable in chronic heart failure (CHF), as generalized systemic neurohumoral activation has been described as the pathophysiological basis of this syndrome. The aim of this study was to examine the prevalence and prognostic value of AE with respect to different \u03b2-blocker agents and doses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>This was a prospective, observational study of 415 patients with systolic CHF receiving chronic stable \u03b2-blocker therapy. AE was defined by norepinephrine levels above the upper limit of normal. Irrespective of the individual \u03b2-blocker agents used and the dose equivalent taken, the prevalence of AE was 31\u201339%. Norepinephrine levels neither correlated with heart rate (r = 0.02; 95% CI: \u22120.08\u20130.11; P = 0.74) nor were they related to underlying rhythm (P = 0.09) or the individual \u03b2-blocker agent used (P = 0.87). The presence of AE was a strong and independent indicator of mortality (adjusted HR: 1.915; 95% CI: 1.387\u20132.645; \u03c72: 15.60).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We verified the presence of AE in CHF patients on chronic stable \u03b2-blocker therapy, irrespective of the individual \u03b2-blocker agent and the dose equivalent. As AE might indicate therapeutic failure, the determination of AE could help to identify those patients with CHF that might benefit from more aggressive treatment modalities. Heart rate, however, is not a surrogate for adrenergic escape.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurjhf\/hfn028","type":"journal-article","created":{"date-parts":[[2009,1,23]],"date-time":"2009-01-23T05:58:02Z","timestamp":1232690282000},"page":"178-184","source":"Crossref","is-referenced-by-count":10,"title":["Prevalence and Prognostic Significance of Adrenergic Escape During Chronic \u03b2-Blocker Therapy in Chronic Heart Failure"],"prefix":"10.1093","volume":"11","author":[{"given":"Lutz","family":"Frankenstein","sequence":"first","affiliation":[{"name":"Department of Cardiology, Angiology, Pulmology, University of Heidelberg , 69120, Heidelberg ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Zugck","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Angiology, Pulmology, University of Heidelberg , 69120, Heidelberg ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dieter","family":"Schellberg","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Angiology, Pulmology, University of Heidelberg , 69120, Heidelberg ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manfred","family":"Nelles","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Angiology, Pulmology, University of Heidelberg , 69120, Heidelberg ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanna","family":"Froehlich","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Angiology, Pulmology, University of Heidelberg , 69120, Heidelberg ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugo","family":"Katus","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Angiology, Pulmology, University of Heidelberg , 69120, Heidelberg ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Remppis","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Angiology, Pulmology, University of Heidelberg , 69120, Heidelberg ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2009,1,28]]},"reference":[{"key":"2026020203392238900_ejhfhfn028-bib-0001","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/eurheartj\/16.suppl_N.103","article-title":"Aldosterone escape during ACE inhibitor therapy in chronic heart failure","volume":"16","author":"Struthers","year":"1995","journal-title":"Eur Heart J"},{"key":"2026020203392238900_ejhfhfn028-bib-0002","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1161\/01.CIR.0000030935.89559.04","article-title":"Elevated plasma aldosterone levels despite complete inhibition of the vascular angiotensin-converting enzyme in chronic heart failure","volume":"106","author":"Jorde","year":"2002","journal-title":"Circulation"},{"key":"2026020203392238900_ejhfhfn028-bib-0003","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0002-9149(01)02261-5","article-title":"Relation of aldosterone \u2018escape\u2019 despite angiotensin-converting enzyme inhibitor administration to impaired exercise capacity in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy","volume":"89","author":"Cicoira","year":"2002","journal-title":"Am J Cardiol"},{"key":"2026020203392238900_ejhfhfn028-bib-0004","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1053\/euhj.1998.1093","article-title":"Two-year time course and significance of neurohumoral activation in the Survival and Ventricular Enlargement (SAVE) study","volume":"19","author":"Vantrimpont","year":"1998","journal-title":"Eur Heart J"},{"key":"2026020203392238900_ejhfhfn028-bib-0005","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1161\/01.CIR.95.1.169","article-title":"Increased cardiac adrenergic drive precedes generalized sympathetic activation in human heart failure","volume":"95","author":"Rundqvist","year":"1997","journal-title":"Circulation"},{"key":"2026020203392238900_ejhfhfn028-bib-0006","first-page":"IV80","article-title":"Role of neurohormonal mechanisms in determining survival in patients with severe chronic heart failure","volume":"75","author":"Packer","year":"1987","journal-title":"Circulation"},{"key":"2026020203392238900_ejhfhfn028-bib-0007","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJM198409273111303","article-title":"Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure","volume":"311","author":"Cohn","year":"1984","journal-title":"N Engl J Med"},{"key":"2026020203392238900_ejhfhfn028-bib-0008","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S0735-1097(01)01383-3","article-title":"Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction","volume":"38","author":"Stanek","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"2026020203392238900_ejhfhfn028-bib-0009","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/j.1475-097X.2006.00693.x","article-title":"Effect of adrenergic blockade on plasma adrenomedullin concentration during static handgrip in patients with heart failure","volume":"26","author":"Krzeminski","year":"2006","journal-title":"Clin Physiol Funct Imaging"},{"key":"2026020203392238900_ejhfhfn028-bib-0010","first-page":"549","article-title":"Neurohumoral changes in patients with heart failure treated chronically with beta-blockers","volume":"36","author":"Mattioli","year":"1991","journal-title":"Cardiologia"},{"key":"2026020203392238900_ejhfhfn028-bib-0011","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1016\/j.peptides.2006.02.010","article-title":"Neurohormones and inflammatory mediators in patients with heart failure undergoing cardiac resynchronization therapy: time courses and prediction of response","volume":"27","author":"Boriani","year":"2006","journal-title":"Peptides"},{"key":"2026020203392238900_ejhfhfn028-bib-0012","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/0735-1097(94)90114-7","article-title":"Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study","volume":"24","author":"Eichhorn","year":"1994","journal-title":"J Am Coll Cardiol"},{"key":"2026020203392238900_ejhfhfn028-bib-0013","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1161\/01.CIR.94.11.2817","article-title":"Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart","volume":"94","author":"Gilbert","year":"1996","journal-title":"Circulation"},{"key":"2026020203392238900_ejhfhfn028-bib-0014","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.healun.2007.07.030","article-title":"Beta-blockers influence the short-term and long-term prognostic information of natriuretic peptides and catecholamines in chronic heart failure independent from specific agents","volume":"26","author":"Frankenstein","year":"2007","journal-title":"J Heart Lung Transplant"},{"key":"2026020203392238900_ejhfhfn028-bib-0015","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1093\/eurheartj\/ehi204","article-title":"Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology","volume":"26","author":"Swedberg","year":"2005","journal-title":"Eur Heart J"},{"key":"2026020203392238900_ejhfhfn028-bib-0016","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0009-8981(83)90002-5","article-title":"Plasma free and conjugated catecholamines in diagnosis and localisation of pheochromocytoma","volume":"132","author":"Ratge","year":"1983","journal-title":"Clin Chim Acta"},{"key":"2026020203392238900_ejhfhfn028-bib-0017","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1056\/NEJM199906173402404","article-title":"Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2","volume":"340","author":"Eisenhofer","year":"1999","journal-title":"N Engl J Med"},{"key":"2026020203392238900_ejhfhfn028-bib-0018","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.cccn.2003.08.016","article-title":"Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay","volume":"338","author":"Yeo","year":"2003","journal-title":"Clin Chim Acta"},{"key":"2026020203392238900_ejhfhfn028-bib-0019","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/01.CIR.100.10.1056","article-title":"Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators","volume":"100","author":"McKelvie","year":"1999","journal-title":"Circulation"},{"key":"2026020203392238900_ejhfhfn028-bib-0020","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1161\/01.CIR.0000141297.50027.A4","article-title":"Effect of baseline or changes in adrenergic activity on clinical outcomes in the beta-blocker evaluation of survival trial","volume":"110","author":"Bristow","year":"2004","journal-title":"Circulation"},{"key":"2026020203392238900_ejhfhfn028-bib-0021","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.ejheart.2004.04.013","article-title":"The clinical implications of aldosterone escape in congestive heart failure","volume":"6","author":"Struthers","year":"2004","journal-title":"Eur J Heart Fail"},{"key":"2026020203392238900_ejhfhfn028-bib-0022","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1136\/hrt.82.1.57","article-title":"How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure?","volume":"82","author":"MacFadyen","year":"1999","journal-title":"Heart"},{"key":"2026020203392238900_ejhfhfn028-bib-0023","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1161\/01.CIR.94.3.353","article-title":"Acute effects of beta 1-selective and nonselective beta-adrenergic receptor blockade on cardiac sympathetic activity in congestive heart failure","volume":"94","author":"Newton","year":"1996","journal-title":"Circulation"},{"key":"2026020203392238900_ejhfhfn028-bib-0024","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1054\/S1071-9164(03)00133-7","article-title":"A comparative analysis of the results from 4 trials of beta-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS","volume":"9","author":"Domanski","year":"2003","journal-title":"J Card Fail"},{"key":"2026020203392238900_ejhfhfn028-bib-0025","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.ahj.2007.03.010","article-title":"Beta-blocker dosing in community-based treatment of heart failure","volume":"153","author":"Fowler","year":"2007","journal-title":"Am Heart J"},{"key":"2026020203392238900_ejhfhfn028-bib-0026","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0735-1097(02)01970-8","article-title":"Dose of metoprolol CR\/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR\/XL randomized intervention trial in chronic heart failure (MERIT-HF)","volume":"40","author":"Wikstrand","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"2026020203392238900_ejhfhfn028-bib-0027","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jacc.2004.10.032","article-title":"What resting heart rate should one aim for when treating patients with heart failure with a beta-blocker? Experiences from the Metoprolol Controlled Release\/Extended Release Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF)","volume":"45","author":"Gullestad","year":"2005","journal-title":"J Am Coll Cardiol"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1093%2Feurjhf%2Fhfn028","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/11\/2\/178\/66547513\/eurjhf_11_2_178.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/11\/2\/178\/66547513\/eurjhf_11_2_178.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T08:39:35Z","timestamp":1770021575000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/11\/2\/178\/8439034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1,28]]},"references-count":27,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2009,1,28]]},"published-print":{"date-parts":[[2009,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/eurjhf\/hfn028","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1159358.619705","asserted-by":"object"}]},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2009,2]]},"published":{"date-parts":[[2009,1,28]]}}}